Trials / Available
AvailableNCT05119257
(Bispecific) Antibodies in Cancer Patients
(Bispecific) Antibodies in Cancer Patients (InHeAb01)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The aim of this project is to provide (bispecific) antibodies to individual patients with advanced solid and hematological malignancies without any available approved treatment options.
Detailed description
Ethics: Patient treatment will be conducted according to §13 Absatz 2b, AMG (German law). All (bispecific antibodies) applied are developed and manufactured by the principle investigator Prof. Helmut Salih.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bispecific antibodies (bsAB) | BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity. |
Timeline
- First posted
- 2021-11-15
- Last updated
- 2024-05-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05119257. Inclusion in this directory is not an endorsement.